Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for Viking Therapeutics, Inc. Common Stock (VKTX).
- Disclosed ownership: 4.5%.
- Date of event: 31 Mar 2025.
BlackRock, Inc. - 31 Mar 2025 SCHEDULE 13G/A Report for Viking Therapeutics, Inc. Common Stock (VKTX)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- VKTX
- Shares outstanding
- 111,811,356 shares
- Disclosed Ownership
- 5,031,511 shares
- Ownership
- 4.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 23 Apr 2025, 10:00:08 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 04 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 4.5% ownership in Viking Therapeutics, Inc. Common Stock (VKTX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 04 Feb 2025.
- Current filing was accepted on 23 Apr 2025, 10:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 4.5% | 5,031,511 | 4,807,647 | 0 | Spencer Fleming | Managing Director |